Skip to main content
Clinical Trials/ISRCTN26091555
ISRCTN26091555
Completed
Not Applicable

Randomised trial of detrusor botulinum toxin injection compared to placebo in idiopathic detrusor overactivity

niversity Hospitals of Leicester NHS Trust (UK)0 sites240 target enrollmentMay 26, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Detrusor overactivity
Sponsor
niversity Hospitals of Leicester NHS Trust (UK)
Enrollment
240
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 26, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
niversity Hospitals of Leicester NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. 8 weeks of continued treatment with oral anticholinergic medication, with a screening Patient Global Impression of Improvement (PGI\-I) scale score of 'a little better' or 'worse'. This point of the scale represents a reduction of incontinence episode frequency of around 50% (Slack, unpublished data).
  • 2\. 8 weeks of continued treatment, with a verbal response that the treatment has not provided acceptable improvement
  • 3\. Treatment stopped because of side effects within 8 weeks
  • 4\. Previous treatments stopped because of lack of efficacy, and currently receiving no treatment
  • Additionally, patients will report at least 8 voids per 24 hours, with at least 2 urgency episodes per 24 hours. Urgency episodes will be defined as those rated as 'moderate' or higher on the Urgency severity scale, and urge incontinence episodes will be defined as recorded leakage in association with an urgency episode.

Exclusion Criteria

  • 1\. Patients with known multiple sclerosis, stroke, spinal injury, or other neurological disease
  • 2\. Patients with pre\-existing voiding dysfunction (flow rate less than 5th centile, or post void residual volume greater than 100 ml)
  • 3\. Patients fulfilling the exclusion criteria for the licensed indications of botulinum toxin (myasethenia gravis and Eaton Lambert syndrome, or allergy to constituents of BOTOX® injection)
  • 4\. Patients with co\-existing urodynamic stress incontinence

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Randomised trial of detrusor botulinum toxin injection (BOTOX®) compared to placebo in women with idiopathic detrusor overactivityDetrusor overactivity which is a disease of bladder function where unprovoked contractions of the detrusor muscle are generated during the storage phase of micturition. Symptoms include frequency, urgency, urge incontinence, nocturia. The first line treatment for this condition is with oral anticholinergic medication, which in many patients is ineffective.
EUCTR2004-002981-39-GBniversity Hospitals of Leicester NHS Trust240
Recruiting
Phase 4
Botulinum toxin injections into the salivary glands to reduce drooling in childreExcessive drooling in children with neurological disordersNeurological - Other neurological disorders
ACTRN12605000379617Murdoch Children's Research Institute56
Completed
Not Applicable
The effects of botulinum toxin (BoNT) injection on sleep bruxism (SB) episodes
KCT0004459Yonsei University Health System, Dental Hospital30
Completed
Not Applicable
Study of safety and duration of action of single dose (7.5 units) of botulinum toxin injection in patients with functional epiphora and proximal lacrimal drainage blockHealth Condition 1: H042- Epiphora
CTRI/2021/03/031793Dept of Ophthalmology Command Hospital Kolkata31
Recruiting
Phase 3
botulinum toxin A in emotional movements of the nostrilsrhinoplasty.Encounter for other plastic and reconstructive surgery following medical procedure or healed injuryZ42.8
IRCT20230418057953N1Esfahan University of Medical Sciences60